(Q36361469)

13 August 2017

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml (English)

1 reference

13 August 2017

1 reference

R H A Becker

1

1 reference

13 August 2017

I Nowotny

2

1 reference

13 August 2017

L Teichert

3

1 reference

13 August 2017

K Bergmann

4

1 reference

13 August 2017

C Kapitza

5

1 reference

13 August 2017

7 January 2015

1 reference

Diabetes, Obesity and Metabolism

13 August 2017

1 reference

13 August 2017

17

1 reference

13 August 2017

3

1 reference

13 August 2017

261-267

1 reference

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

Hypoglycemia is the limiting factor in the management of diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4674964

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

22 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25425394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25425394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25425394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/DOM.12416

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

25425394

1 reference